# Development of Chronic Kidney Disease Screening Integrative Care Model Led by Community Pharmacists

**Authors:** Piangkwan Srimongkhol, Sirirat Anutrakulchai, Amponpun Theeranut, Nonglak Methakanjanasak, Sunee Lertsinudom

PMC · DOI: 10.3390/pharmacy13010027 · Pharmacy · 2025-02-14

## TL;DR

Community pharmacists can help prevent chronic kidney disease by screening for albuminuria and supporting self-management behaviors.

## Contribution

This study introduces a pharmacist-led care model for CKD prevention through screening and behavior modification.

## Key findings

- 57% of 521 participants tested positive for albuminuria, prompting referrals and serum creatinine testing.
- Self-management behavior scores improved significantly (p = 0.024) in participants with albuminuria.
- Key factors like diabetes and hypertension were strongly associated with higher urine albumin levels.

## Abstract

Background: The prevalence of chronic kidney disease (CKD) is rising, increasing demand for renal replacement therapy (RRT). Community pharmacies, as accessible healthcare hubs, can play a pivotal role in CKD prevention. This study aimed to develop care models for community pharmacies to optimize medication use, encourage behavior modification, and promote self-management among at-risk individuals. Methods: Conducted between June 2017 and July 2018, this study utilized an action research approach. Microalbuminuria was assessed using urine dipsticks, and pharmacists applied behavioral change and self-management support (SMS) strategies to slow CKD progression. Participants were categorized by albuminuria levels and enrolled in pharmacist-led care programs, with follow-up assessments at weeks 0 and 12. Results: Of 521 participants screened, 57% tested positive for albuminuria. For these individuals, serum creatinine testing and referrals to primary care were initiated. Self-management behavior assessment (S1) scores significantly improved (p = 0.024). Key factors associated with urine albumin levels included age < 60 years (OR = 0.44), diabetes (OR = 3.69), hypertension (OR = 2.01), BMI < 27.5 kg/m2 (OR = 0.42), eGFR ≥ 60 mL/min/1.73 m2 (OR = 3.34), lower systolic (OR = 0.55) and diastolic blood pressure (OR = 0.34), and fasting plasma glucose < 126 mg/dL (OR = 0.29). Conclusions: Community pharmacist-led albuminuria screening effectively supports CKD prevention and enhances self-awareness within communities.

## Linked entities

- **Diseases:** chronic kidney disease (MONDO:0005300), diabetes (MONDO:0005015)

## Full-text entities

- **Diseases:** diabetes (MESH:D003920), hypertension (MESH:D006973), albuminuria (MESH:D000419), CKD (MESH:D051436)
- **Chemicals:** glucose (MESH:D005947), creatinine (MESH:D003404)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11858870/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11858870/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC11858870/full.md

---
Source: https://tomesphere.com/paper/PMC11858870